Profile data is unavailable for this security.
About the company
NIOX Group plc is a United Kingdom-based diagnostics and management company that is focused on asthma. The Company is engaged in the design, development, and commercialization of medical devices for the measurement of fractional exhaled nitric oxide (FeNO), a precise biomarker for asthma. The Company's NIOX FeNO measurement and monitoring products are used by physicians around the globe to help improve asthma diagnosis and management. The Company offers NIOX VERO, a point of care device for the accurate measurement of nitric oxide (NO) as a biomarker of airway inflammation to help diagnose and manage asthma. The device is used by healthcare professionals to improve asthma care, which assists diagnosis, determining responsiveness to inhaled corticosteroids, tailoring inhaled steroid use, monitoring treatment compliance, and reducing the likelihood of exacerbations in at-risk patients compared to traditional monitoring. The Company offers products and services in around 50 countries.
- Revenue in GBP (TTM)39.00m
- Net income in GBP11.00m
- Incorporated2006
- Employees85.00
- LocationNiox Group PLCHayakawa BuildingThe Oxford Science ParkOXFORD OX4 4GBUnited KingdomGBR
- Phone+44 186 540 5560
- Fax+44 186 578 4576
- Websitehttps://investors.niox.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PharmaSGP Holding SE | 92.61m | 15.37m | 249.07m | 93.00 | 16.20 | 9.05 | 10.70 | 2.69 | 1.52 | 1.52 | 9.15 | 2.72 | 0.8223 | 1.04 | 8.57 | 1,233,225.00 | 13.64 | 13.70 | 18.34 | 19.98 | 90.91 | 90.20 | 16.59 | 17.56 | 1.54 | 14.98 | 0.6823 | -- | 17.80 | 10.78 | 37.17 | 2.16 | 25.88 | -- |
| Adimmune Corp | 40.22m | -14.76m | 252.90m | 564.00 | -- | 2.03 | -- | 6.29 | -1.44 | -1.44 | 3.93 | 11.92 | 0.1848 | 1.25 | 4.04 | -- | -8.27 | 0.6867 | -10.19 | 0.7739 | 27.82 | 30.11 | -44.75 | 3.04 | 1.99 | -24.75 | 0.3284 | 32.80 | -20.72 | 16.77 | -319.91 | -- | 38.05 | -- |
| Seikagaku Corp | 186.50m | 11.22m | 254.36m | 988.00 | 21.77 | 0.641 | 12.58 | 1.36 | 40.32 | 40.32 | 670.36 | 1,369.69 | 0.4558 | 2.01 | 4.65 | 37,018,220.00 | 2.74 | 0.4261 | 2.96 | 0.4678 | 47.46 | 54.18 | 6.01 | 0.9814 | 5.04 | -- | 0.0052 | 465.78 | 8.24 | 4.99 | -2.24 | -0.5224 | 30.28 | 0.00 |
| Flerie AB | 7.28k | -19.63m | 255.81m | 2.00 | -- | 0.8243 | -- | 35,129.88 | -22.07 | -22.07 | 0.0019 | 54.59 | 0.00004 | -- | -- | 14,285.71 | -11.53 | -37.64 | -11.69 | -41.14 | -92,017.00 | -450.51 | -269,618.00 | -454.62 | -- | -2.58 | 0.0002 | -- | -- | 277.02 | 5.05 | -- | -- | -- |
| Niox Group PLC | 39.00m | 11.00m | 256.30m | 85.00 | 26.42 | 3.34 | 16.75 | 6.57 | 0.0244 | 0.0259 | 0.0864 | 0.1929 | 0.4255 | 2.86 | 8.76 | 458,823.50 | 12.00 | -2.41 | 12.88 | -2.90 | 71.79 | 70.87 | 28.21 | -11.46 | 5.56 | -- | 0.0109 | -- | 17.57 | -5.29 | -32.62 | -- | -5.59 | -- |
| SCI Pharmtech Inc | 30.40m | 3.36m | 260.00m | 241.00 | 79.05 | 2.12 | 32.41 | 8.55 | 1.13 | 1.13 | 12.70 | 42.26 | 0.2044 | 1.61 | 3.83 | -- | 2.26 | 6.90 | 2.54 | 8.26 | 27.75 | 38.18 | 11.06 | 19.85 | 1.78 | 802.61 | 0.1826 | 42.38 | 33.83 | -9.10 | -4.55 | -8.00 | 44.67 | -16.35 |
| Formosa Laboratories Inc | 113.88m | 6.21m | 262.80m | 480.00 | 42.62 | 1.44 | 18.03 | 2.31 | 2.11 | 2.11 | 38.90 | 62.49 | 0.3479 | 1.49 | 4.42 | -- | 0.7067 | 2.68 | 0.9689 | 3.61 | 44.30 | 35.40 | 2.03 | 8.75 | 1.18 | 0.8922 | 0.3155 | 27.38 | 15.80 | 10.16 | -69.16 | -6.52 | -11.60 | 32.22 |
| Indoco Remedies Ltd | 163.48m | 2.95m | 263.71m | 5.93k | 93.03 | 2.63 | 20.98 | 1.61 | 3.34 | 3.34 | 175.26 | 118.23 | 0.8194 | 1.52 | 4.51 | 2,989,727.00 | 1.36 | 6.88 | 1.99 | 9.85 | 68.34 | 65.59 | 1.66 | 6.93 | 0.8142 | 1.71 | 0.4339 | 14.02 | 8.91 | 13.41 | -30.78 | -- | 34.54 | 37.97 |
| Holder | Shares | % Held |
|---|---|---|
| Harwood Capital LLPas of 29 May 2024 | 75.82m | 17.88% |
| Lombard Odier Asset Management (Europe) Ltd.as of 07 Aug 2020 | 18.13m | 4.28% |
| Rathbones Investment Management Ltd.as of 19 Jun 2024 | 17.86m | 4.21% |
| Invesco Asset Management Ltd.as of 16 Jan 2020 | 15.66m | 3.69% |
| Danske Bank A/S (Investment Management)as of 27 Jan 2022 | 13.48m | 3.18% |
| Morgan Stanley Smith Barney LLC (Investment Management)as of 01 Aug 2024 | 9.71m | 2.29% |
| Merchant Capital Manager Ltd.as of 19 Aug 2020 | 8.67m | 2.04% |
| Schroder & Co Bank AG (Private Banking)as of 01 Aug 2024 | 5.99m | 1.41% |
| JPMorgan Asset Management (UK) Ltd.as of 01 Aug 2024 | 5.78m | 1.36% |
| Brooks Macdonald Asset Management Ltd.as of 01 Aug 2024 | 5.54m | 1.31% |
